Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Teratoma 1Neoplasms, Germ Cell and Embryonal 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Endodermal Sinus Tumor 1Carcinoma, Embryonal 1

Interventions

pembrolizumab 81Carboplatin 76Magnetic Resonance Spectroscopy 73Specimen Handling 69Cisplatin 62Paclitaxel 55Gemcitabine 46Fluorouracil 37Dexamethasone 37Radiation 36Docetaxel 36Cyclophosphamide 36Radiotherapy 35Pemetrexed 35Doxorubicin 35Oxaliplatin 33Leucovorin 33Bevacizumab 31Capecitabine 28Vincristine 27durvalumab 26Etoposide 24Rituximab 23Taxes 22Irinotecan 22Nivolumab 21Letrozole 21Prednisone 20Biopsy 20Platinum 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Bleomycin × 30 days × Clear all
NCT05675410 2026-05-27

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT03067181 2026-05-05

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Children's Oncology Group

Phase 3 Recruiting
1,780 enrolled

Neoplasms, Germ Cell and Embryonal, Teratoma, Carcinoma, Embryonal, Endodermal Sinus Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡